

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.,
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2023-00442
Patent No. 10,130,681 B2

**PATENT OWNER'S SECOND SET OF
OBJECTIONS TO PETITIONER'S EXHIBITS**

Pursuant to 37 C.F.R. § 42.64(b)(1), Patent Owner Regeneron Pharmaceuticals, Inc. (“Patent Owner”), submits the following objections to Petitioner Samsung Bioepis Co., Ltd.’s (“Petitioner’s”) Exhibits 1064–81, and any reference to and/or reliance on the foregoing, including, without limitation, citations or references thereto in Petitioner’s Reply (Paper 40). Patent Owner’s objections below apply the Federal Rules of Evidence (“FRE”) as required by 37 C.F.R. § 42.62.

These objections supplement Patent Owner’s Objections to Petitioner’s Exhibits (Paper 17), served August 2, 2023, which Patent Owner maintains.

Exhibit 1071 - Exhibit 1071 is objected to under FRE 401, 402 and 403. Exhibit 1071 is not relevant, and its probative value is substantially outweighed by the danger of confusion of the issues and misleading the fact finder because Petitioner has not demonstrated that it was published before the January 13, 2011 priority date of the challenged claims of U.S. Patent No. 10,130,681 (the “’681 Patent”). Exhibit 1071 is also objected to under FRE 901 and FRE 802 as unauthenticated and hearsay evidence. It is not clear where the exhibit came from or how it was compiled.

Exhibit 1072 - Exhibit 1072 is objected to under FRE 401, 402 and 403. Exhibit 1072 is not relevant, and its probative value is substantially outweighed by the danger of confusion of the issues and misleading the fact finder because Petitioner has not demonstrated that it was published before the January 13, 2011

priority date of the challenged claims of the '681 Patent. Exhibit 1072 is also objected to under FRE 901 and FRE 802 as unauthenticated and hearsay evidence. It is not clear where the exhibit came from or how it was compiled.

Exhibit 1078 - Exhibit 1078 is objected to under FRE 401, 402 and 403. Exhibit 1078 is not relevant, and its probative value is substantially outweighed by the danger of confusion of the issues and misleading the fact finder because it was not published before the January 13, 2011 priority date of the challenged claims of the '681 Patent.

Exhibit 1079 - Exhibit 1079 is objected to under FRE 401, 402 and 403. Exhibit 1079 is not relevant, and its probative value is substantially outweighed by the danger of confusion of the issues and misleading the fact finder because it was not published before the January 13, 2011 priority date of the challenged claims of the '681 Patent.

Exhibit 1080 - Exhibit 1080 is objected to under FRE 901 and FRE 802 as unauthenticated and hearsay evidence. It is not clear where the exhibit came from or how it was compiled. Exhibit 1080 is also objected to under FRE 106. Petitioner has filed what appears to be an incomplete excerpt from a larger reference. The remainder of the text has not been introduced or filed by Petitioner, but in fairness ought to be considered at the same time as those pages that were provided.

Case IPR2023-00442
Patent 10,130,681 B2

Dated: January 23, 2024

Respectfully Submitted,

/Deborah E. Fishman/

Deborah E. Fishman (Reg. No. 48,621)
3000 El Camino Real #500
Palo Alto, CA 94304

**Counsel for Patent Owner,
Regeneron Pharmaceuticals, Inc.**

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e)(4)(i) *et seq.*, the undersigned Certifies that on January 23, 2024, a true and entire copy of this **PATENT OWNER'S SECOND SET OF OBJECTIONS TO PETITIONER'S EXHIBITS** was served via e-mail to the Petitioner at the following email addresses:

qe-samsungbioepis@quinnemanuel.com
raynimrod@quinnemanuel.com
matthewtraupman@quinnemanuel.com
elliotochoi@quinnemanuel.com
zachsummers@quinnemanuel.com
sarahcork@quinnemanuel.com
landonsmith@quinnemanuel.com

/Deborah E. Fishman/

Deborah E. Fishman (Reg. No. 48,621)
3000 El Camino Real #500
Palo Alto, CA 94304

**Counsel for Patent Owner,
Regeneron Pharmaceuticals, Inc.**